| Bioactivity | PD-L1-IN-6 (Compound 16) is an orally active inhibitor for PD-L1 expression in neutrophil by targeting STAT3 with KD of 90.5 nmol/L. PD-L1-IN-6 promotes neutrophil-mediated antifungal immunoresponse[1]. |
| Invitro | PD-L1-IN-6 (40 μM) 在 40 μM 时可抑制 80.17% PD-L1 表达，且对中性粒细胞无明显细胞毒性[1]。PD-L1-IN-6 对血脑屏障具有微透性，pe为1.22×10-6 cm/s[1]。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. 0 --> PD-L1-IN-6 相关抗体: Cell Viability Assay[1] Cell Line: |
| In Vivo | PD-L1-IN-6 (50-100 mg/kg,，口服，3 天) 在 C. albicans 感染的C57BL/6 小鼠模型中，抑制 β-葡聚糖诱导的 CXCL1 和 CXCL2 分泌，诱导中性粒细胞迁移，增强中性粒细胞介导的抗真菌免疫[1]。PD-L1-IN-6 在 SD 大鼠体内的药代动力学分析[1]route |
| Formula | C21H24Cl2O6S |
| Molar Mass | 475.38 |
| Transport | Room temperature in continental US; may vary elsewhere. |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Lu X, et al., Drug Repurposing of ACT001 to Discover Novel Promising Sulfide Prodrugs with Improved Safety and Potent Activity for Neutrophil-Mediated Antifungal Immunotherapy. J Med Chem. 2024 Mar 25. |